Menin is necessary for long term maintenance of meningioma-1 driven leukemia

Translocations of Meningioma-1 (MN1) occur in a subset of acute myeloid leukemias (AML) and result in high expression of MN1, either as a full-length protein, or as a fusion protein that includes most of the N-terminus of MN1. High levels of MN1 correlate with poor prognosis. When overexpressed in murine hematopoietic progenitors, MN1 causes an aggressive AML characterized by an aberrant myeloid precursor-like gene expression program that shares features of KMT2A-rearranged (KMT2A-r) leukemia, including high levels of Hoxa and Meis1 gene expression. Compounds that target a critical KMT2A–Menin interaction have proven effective in KMT2A-r leukemia. Here, we demonstrate that Menin (Men1) is also critical for the self-renewal of MN1-driven AML through the maintenance of a distinct gene expression program. Genetic inactivation of Men1 led to a decrease in the number of functional leukemia-initiating cells. Pharmacologic inhibition of the KMT2A–Menin interaction decreased colony-forming activity, induced differentiation programs in MN1-driven murine leukemia and decreased leukemic burden in a human AML xenograft carrying an MN1-ETV6 translocation. Collectively, these results nominate Menin inhibition as a promising therapeutic strategy in MN1-driven leukemia.


Introduction
Acute myeloid leukemia (AML) is a heterogenous disease characterized by the clonal proliferation of myeloid cells arrested at an early stage of differentiation. Genome-wide sequencing efforts have allowed the identification of a large number of molecular abnormalities [1,2], but for the most part, the exact contribution of each abnormality to leukemogenesis remains unclear.
MN1 remains poorly characterized both functionally and structurally. Some evidence suggests that MN1 can act as transcriptional activator [14,15]. Forced expression of MN1 in murine bone marrow causes the development of an aggressive leukemia. Early myeloid progenitors were found to be particularly susceptible to MN1 overexpression as their high level of Hoxa9 and Meis1 expression is a transcriptional requirement for MN1-mediated transformation [16]. MN1driven leukemic cells harbor an aberrant gene expression program characterized by genes that are normally downregulated at the transition from common myeloid progenitors (CMP) to granulocytes macrophages progenitors, such as Hoxa9 and Meis1 [16]. A similar gene expression requirement exists in human CD34 + cord blood cells, where MN1 alone is insufficient to induce leukemia but needs cooperation with high HOX cluster gene expression mediated for example by the NUP98-HOXD13 fusion [17].
HOX genes and their co-factor MEIS1 are target genes of both KMT2A-fusions and wild-type KMT2A proteins [18]. We previously found that loss of Kmt2a led to downregulation of the aberrant "MN1-driven leukemic program", suggesting that the aberrant expression of Hoxa9 and Meis1 in MN1-driven leukemia remained under the control of its physiologic regulator, Kmt2a [19].
KMT2A, the human homolog of the Drosophila Trithorax [20], can target chromatin through multiple distinct domains. The KMT2A C-terminus contains a conserved Su (var)3-9, enhancer of zeste trithorax (SET) domain, involved in methylation of lysine 4 at histone 3 (H3K4me) [21,22]. The N-terminal region contains DNA-binding domains: three AT hooks [23] and a CxxC domain [24]. The N-terminus also contains a binding domain for Menin, a scaffold protein, that allows another level of chromatin interaction via LEDGF.
Menin is the product of the gene Multiple Endocrine Neoplasia Type 1 (MEN1) [25] and has context-specific functions. It is a bonafide tumor suppressor gene in neuroendocrine tissues [26]. On the other hand, Menin is absolutely necessary for the maintenance of aberrant gene expression by KMT2A-fusion proteins in the hematopoietic system [27,28].
Here, we present evidence that while the SET domain of Kmt2a is not required for MN1-mediated transformation, Menin plays a major role in sustaining the MN1-driven leukemic program. Together with our previous findings of a requirement for Kmt2a, our data suggest that MN1 drives a leukemic program mediated by the Menin/Kmt2a complex, and that disrupting this complex represents a new therapeutic strategy in MN1-driven AML.

Material and methods
For primer sequences, antibodies, and detailed experimental procedures, please refer to the Supplementary Methods.

Generation of murine MN1-driven leukemia
All experiments were conducted in accord with the principles and procedures outlined in the Internal Animal Care and Use Committee.
Apoptosis assays of murine MN1-driven leukemic cells Menin/Kmt2a inhibition in murine MN1-driven AML MN1-driven leukemic cells (Men1 wt background) or control cells were plated in M3234 (STEMCELL TM technologies, Vancouver, CANADA) supplemented with 10 ng/ml murine IL3 and IL6 and 20 ng/ml murine SCF (Preprotech Inc, Rocky Hill, NJ, USA 10% P/S and IMDM (Corning®, Corning, NY, USA) at a concentration of 500 cells per plate, in duplicates. VTP50469 (Syndax®) or DMSO was added at the indicated concentration. Every 5 days, colonies were scored based upon morphology and total cell numbers counted. Cells were then replated at the same concentration in fresh methylcellulose with fresh drug.

Menin/KMT2A inhibition in human AML
Cells were plated in duplicates and VTP50469 (Syndax®) or DMSO control was added at the indicated concentration. Cell growth and viability were determined by trypan blue exclusion staining every 3 days and cells were replated in fresh media with fresh drug at equal densities for 16 days.
UCSD-AML1 Xenograft model NSGS (NOD-scid IL2Rgnull-3/GM/SF) were obtained from Jackson laboratories® and maintained under specific pathogen free conditions. Two million UCSD-AML1 cells were resuspended in PBS (Life Technologies, Carlsbad, CA, USA) and injected into the tail vein. Two weeks after the transplantation, mice were placed on VTP50469 0.1% chow or control chow. Myeloblasts were detected in peripheral blood, bone marrow and spleen after staining with a combination of anti-human CD45 (Alexa 700) and antimouse CD45 (FITC) antibodies. A first cohort was treated with VTP50269 for 25 days and sacrificed at day 50 to assess for leukemic burden. A second cohort was treated with continuous VTP50269 until animals reached a humanly defined survival endpoint.

RNA extraction, qPCR and RNA-Seq
Men1 −/− and Men1 wt MN1-driven leukemic cells isolated from three independent moribund mice each were thawed and plated in M3234 methylcellulose. For compound experiments, MN1-driven leukemia cells were plated in the presence of the indicated concentration(s) of VTP50469 or DMSO control. After one methylcellulose replating, cell pellets were resuspended in QIAGEN RLT buffer (Hilden, Germany) with 2-Mercaptoethanol (1:100) and frozen at −80°C. For extraction of RNA, samples were warmed to room temperature and extracted using the RNeasy mini kit from QIAGEN (Hilden, Germany) according to manufacturer instructions. Briefly, gDNA was removed by a column, the flow through was mixed 1:1 with 70% ethanol, the RNA was bound to a second column and washed with ethanol. RNA was eluted in water and quantified using a NanoDrop® spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA). For qPCR, RNA was reverse transcribed using qScript cDNA SuperMix (Quantabio) per the manufacturer's instruction. qPCR was performed using PowerUp SYBR Green (Appliedbiosystems). RNA-Seq libraries were prepared from PolyA selected mRNA (eukaryotic), and multiplexed sequencing was conducted on Illumina HiSeq Sequencers to a read depth of 20-30 million per sample.

RNA-seq analysis
Raw Fastq files were aligned using STAR [31] against reference Mus musculus GRCm38. All samples read-counts were quantified by Kallisto [32] (version 0.45.0). Output from Kallisto was then directly imported into DESeq2 [33] in order to detect differentially expressed genes (DEG). DEGs were deemed as genes with False Discovery Rate < 0.05. All analysis was carried using R, version 3.6.3.

Statistical analysis
Statistical analysis of colony and cell numbers, apoptosis, percent expression of markers associated with differentiation, percent expression on GFP + in bone marrow and peripheral blood was performed using the unpaired twotailed Student's t-tests or 2-way Anova (multiple parameters). Statistical analysis of survival was carried out using Kaplan Meyer estimates (Prism 8 software). The frequency of LIC was calculated using the ELDA software [36]. A p value of <0.05 was considered statistically significant.

Results
The histone methyltransferase activity of Kmt2a is dispensable to MN1-mediated transformation We previously found that deletion of Kmt2a in MN1driven leukemia led to a downregulation of the MN1driven leukemic program [19]. The C-terminal SET domain of KMT2A mediates mono-, di-and trimethylation of lysine 4 on histone 3. H3K4me at Hox gene promoters is associated with active transcription [21,37], although the exact function of H3K4me in gene expression is still a matter of debate [38]. In normal hematopoiesis, the SET domain was shown to be dispensable for Kmt2a function [39]. Nevertheless, peptide inhibitors of proteins that interact with KMT2A C-terminus such as WDR5 are reported to have preclinical activity in KMT2ar AML [40]. Therefore, understanding whether the SET domain plays a role in MN1-driven leukemia could have future therapeutic implications.
In order to investigate a role for Kmt2a SET domain, we compared the ability of MN1 to transform bone marrow progenitors of mice with a constitutive homozygous deletion of the SET domain (Kmt2a SET −/− ) with their wild type litter mates (Kmt2a SET wt ). While homozygous deletion of Kmt2a is embryonically lethal, Kmt2a SET −/− animals develop normally despite decreased expression of certain Hox genes (associated with a locus specific decrease in H3K4me1) [29]. Furthermore, they survive into adulthood and present no hematopoietic defects [39].
We expressed human MN1 using a retroviral vector (MN1-GFP) in murine CMPs. GFP + sorted cells were then plated in methylcellulose to assess their serial replating capacity in vitro. We found no difference in the number or the size of colonies between MN1-transformed CMP established from a Kmt2a SET wt or Kmt2a SET −/− animals (Fig. 1A).
In parallel, GFP + sorted cells were injected into sublethally irradiated syngeneic recipients to investigate their ability to establish leukemia in vivo. MN1-transformed Kmt2a SET −/− CMP were able to induce leukemia with the same latency as wild type controls (median survival of 31 days in Kmt2a SET −/− versus 29 days in controls, p = ns) (Fig. 1B). At the time of death, animals in both groups showed similar leukemic burden, as estimated by the percentage of GFP + cells in the bone marrow, elevated white blood count and spleen weight (Fig. 1C).
Thus, the SET domain of Kmt2a (and therefore the corresponding histone methyltransferase activity) is not required for the establishment of MN1-driven leukemia in vitro or in vivo.

Deletion of Men1 impacts colony forming potential in vitro and decreases the number of leukemia initiating cells in vivo
Menin was found to be essential for transformation and maintenance of KMT2A-rearranged leukemias [27,28] and our previous findings suggest that endogenous Kmt2a is required for MN1-driven leukemia [19]. Interestingly, the Menin/KMT2A interaction has also been found to be required in other subtypes of leukemia such as those with NPM1c [41] and C/EBPα mutations [42,43]. Therefore, we next investigated whether the Kmt2a N-terminal interaction partner Menin was required in MN1-driven leukemia. We established in vivo MN1-driven leukemia on a conditional Men1 f/f background and utilized retroviral expression of Cre-recombinase (MSCV-Cre-tdTomato) to excise Men1 alleles. Men1 wt MN1-driven AML cells transduced with Cre served as control (Men1 wt + Cre). In vitro, Men1 f/f + Cre cells formed consistently fewer colonies compared to Men1 wt + Cre cells ( Fig. 2A). However, loss of Men1 did not abolish colony forming ability over four replatings in MN1-driven murine AML.
Leukemia-initiating cells (LIC) are defined as cells capable of giving rise to human AML in immunocompromised mice [44] but constitute only a small subset of the whole leukemia population. To determine if the changes in colony forming ability upon loss of Men1 were secondary to a decrease in the number of LIC, we transplanted Cretransduced Men1 f/f and Men wt MN1-driven leukemic cells at limiting dilutions. We found that at 1 × 10 5 , 1 × 10 4 and 1 × 10 3 Men1 f/f + Cre transplanted mice had a significantly lower leukemic burden on day 21 compared to Men1 wt + Cre (Fig. 2B). Given the highly aggressive nature, rapid growth and high percentage of LICs in this model, the difference in day 21 leukemic burden did not translate into a difference in disease latency in the Men1 f/f + Cre group at the 1 × 10 5 and 1 × 10 4 cell dose level ( Fig. 2C and Supplementary Fig. S1A-C). However, we did note that a substantial number of Men1 f/f + Cre mice succumbed to leukemia that had failed to rearrange both alleles, implying strong selective pressure against loss of Men1 (Supplementary Fig. S1D, E). Remarkably, at the 1 × 10 3 cell dose level, loss of Men1 severely impaired the ability of MN1driven AML cells to establish leukemia (p < 0.0001 Fig. 2C). Overall, the frequency of LIC was significantly lower in Men1 −/− MN1-driven AML (1:69335 (IC95 [1:127285-1:37768])) than in Men1 wt MN1-driven AML (1:1297 (IC95 [1:2684-1:627])), p = 3.3e-21 (Fig. 2C).
Annexin V staining revealed increases in apoptosis ( Supplementary Fig. S2B). To assess if differences were also observed in vivo, we transplanted Men1 −/− MN1driven AML cells isolated from five distinct moribund animals (and matched controls) into secondary irradiated recipients. At D21 post transplantation, we found a significant decrease in peripheral blood leukemic burden in the Men1 −/− versus Men1 wt group (p < 0.0001) (Fig. 3B). Furthermore, Men1 −/− MN1-driven AML cells failed to propagate leukemia in most recipients (13/15), with a failure to rearrange both alleles in one of the animals ( Fig. 3C and Supplementary Fig. S2C, D). This resulted in a dramatic improvement in survival compared to Men1 wt control (Fig. 3C, p < 0.0001).   Table S2). Gene Set Enrichment Analysis (GSEA) revealed downregulation of the MN1-driven leukemic gene expression program in Men1 −/− versus Men1 wt leukemias, a program previously defined by Heuser et al. [16] (Supplementary Table S1) as a group of genes that are upregulated in MN1-driven leukemic cells versus normal bone marrow (Fig. 4B). Moreover, genes that we had previously found to be downregulated upon Kmt2a deletion [19] (Supplementary Table S1) in this model were strongly enriched in Men1 −/− versus Men1 wt MN1-driven AML (Fig. 4C). We also interrogated a gene set defined as genes bound by Menin which exhibit displacement of Menin and transcriptional downregulation upon pharmacologic inhibition of the Menin/KMT2A interaction in a human KMT2A-MLLT3 leukemia cell line [35]. We found this gene set enriched in Men1 −/− versus Men1 wt MN1-driven AML ( Supplementary Fig. S3A). In addition, genes bound by the histone methyltransferase DOT1L and downregulated upon Menin inhibition in KMT2A-MLLT3 leukemia [35] were found to be enriched in Men1 −/− versus Men1 wt MN1driven AML (Supplementary Fig. S3B). We previously demonstrated a role for DOT1L in maintaining transcription of the MN1-leukemogenic program defined by Heuser et al. [16,19]. Taken together, these data are consistent with a core transcriptional program that is regulated by Menin across several AML subtypes. Men1 −/− MN1-driven AML cells are unable to sustain this core leukemogenic gene expression program necessary for long-term maintenance, leading to cell death in vitro and engraftment failure in vivo.
significantly overlapped, suggesting that Menin might mediate the effect of Kmt2a. Therefore, we investigated the effects of pharmacological inhibition of the Menin/Kmt2a interaction in murine MN1-driven AML. We found that inhibition of the Menin/Kmt2a interaction decreased colony formation (Fig. 5A) and cell growth ( Supplementary  Fig. S4A) in methylcellulose in MN1-driven AML cells, but not in control cells driven by retroviral overexpression of Hoxa9 and Meis1. Fifty percent growth inhibition occurred at similar dose levels for MN1-driven AML and Kmt2a-Mllt3 driven murine AML, although it should be noted that in the Kmt2a-Mllt3 model, responses occurred earlier, and higher doses resulted in considerably more profound inhibition ( Fig. 5B and Supplementary Fig. S4B, C). In addition, VTP50369 treatment resulted in downregulation of the key downstream target Meis1 [35,45] (Fig. 5C and Supplementary Fig. S4D). As previously reported for KMT2A-r cells, VTP50469 also caused upregulation of the differentiation marker Cd11b (Supplementary Fig. S4E, F), although cells did not undergo terminal differentiation as demonstrated by the largely maintained blast morphology on cytospin (Supplementary Fig. S4G).
We next wanted to investigate the effect of VTP50469 in human MN1-driven AML. To test a human AML in which MN1 overexpression was likely to be a founding mutation, we used UCSD-AML1 cells, which carry a t(12;22) translocation. In AML cells with this rearrangement, most or all of the coding sequence of MN1 translocates to the Cterminal of ETV6, resulting in very high expression of MN1 either as a full-length protein or as an MN1-ETV6 fusion protein [4,46]. Disruption of the Menin/KMT2A interaction with VTP50469 produced a time-and dose-dependent decrease in proliferation in vitro. This was not the case upon treatment of KASUMI-1 [RUNX1-RUNXT1] cells, a cell line characterized by low HOXA9 and MEIS1 expression (Fig. 6A). Overall, UCSD-AML1 cells displayed sensitivity to VTP50469 with an IC50 that was higher than the highly sensitive MV4;11 [KMT2A-AFF1] and OCI-AML3 [NPM1c] cell lines, similar to Molm-14 [KMT2A-MLLT3], and lower than THP1 [KMT2A-MLLT3] (Fig. 6B and Supplementary Fig. S5). Of note, MV4;11 responded much earlier and much more profoundly at higher doses compared to UCSD-AML1 and the other KMT2A-rearranged cell lines ( Fig. 6B and Supplementary Fig. S5). In order to determine efficacy of VTP50469 in vivo, we established a UCSD-AML1 xenograft model. On D0, NSGS mice were injected with 2 × 10 6 UCSD-AML1 cells. After 14 days, animals were switched onto to VTP50469-containing or control chow (Fig. 6C). We performed a first assessment of leukemia burden at D28 post-transplant/D14 of treatment (TP1). At TP1, we found a small but significant difference between control and drug-treated mice (Fig. 6D). Chow was discontinued after 25 days and mice were sacrificed on D47 post-transplant, 7 days after discontinuing the chow. At TP2, we observed a significant decrease in both the bone marrow and the spleen leukemia burden in VTP50469-treated mice (Fig. 6D). In a second independent experiment, animals were transplanted and treatment was initiated as detailed above, but VTP-50469 or control chow were continued for the remainder of the experiment. Sustained VTP-50469 treatment induced a modest but significant increase of survival in addition to lower leukemic burden (Fig. 6F, G). Overall, pharmacologic inhibition of the Menin/KMT2A interaction decreased cell growth of both murine and human MN1-driven leukemia, with efficacy in vivo. These data underscore the value of targeting the Menin/KMT2A interaction in MN1-driven AML.

Discussion
MN1-driven leukemia is characterized by a CMP-like gene expression program that includes high expression of Hoxa9 and Meis1 [16], known target genes of Kmt2afusion proteins but also of wild type Kmt2a. We previously established that aberrant gene expression in MN1driven leukemia was under the control of wild type Kmt2a [19]. As Kmt2a is involved in chromatin regulation through distinct functional domains and interaction partners, we investigated here which are relevant to MN1mediated transformation.
Using a murine conditional knockout model, we found that loss of Men1 specifically impacts the LIC frequency in MN1-driven AML. In primary recipients, a decrease in the number of LIC was illustrated by the inability of Men1 f/f MN1 leukemic cells transduced with Cre to engraft at lower cell number (<1 × 10 4 cells). In secondary recipients, the decrease in LIC resulted in an almost complete exhaustion of Men1 −/− MN1-driven leukemia cells in vivo. Furthermore, GSEA revealed that a set of genes that we had previously found to be downregulated upon loss of Kmt2a in MN1-driven leukemia was enriched in Men1 −/− versus Men1 wt MN1-driven AML cells. Menin-dependent genes in MN1-AML also contained a core transcriptional program that was found to be dependent on Menin in other subtypes of AML, including those with KMT2A rearrangements and NPM1c [35]. The observation that loss of Men1 and loss of Kmt2a have similar effects on gene expression suggests that such effect is mediated through the Menin/Kmt2a interaction. Indeed, pharmacologic inhibition of the Menin/Kmt2a interaction decreased colony formation and leukemia burden in models of murine and human MN1-driven AML in vivo and in vitro, respectively.
Menin interacts with the N-terminus of both wild type KMT2A [47] and KMT2A fusion proteins [28]. In KMT2Arearranged leukemias, the transcriptional consequences of Men1 deletion/Menin/KMT2A inhibition mirror inactivation of the fusion, not inactivation of the KMT2A wild type allele [48]. The unmutated KMT2A allele is largely dispensable for KMT2A-fusion mediated leukemogenesis [48,49]. Thus, Menin/KMT2A inhibition in KMT2A-fusion leukemias acts via disruption of the fusion complex, not the KMT2A complex. In contrast, Menin/KMT2A inhibition is effective in disrupting KMT2A dependent transcription in leukemia models that exhibit a dependency on KMT2A by preventing recruitment of the Menin/wild type KMT2A complex to a subset of target genes [41,45]. Interestingly, among the key canonical targets of KMT2A or KMT2Afusions in these models, MEIS1, but not HOXA cluster gene expression was found to be directly dependent on Menin. This suggest that the observed downregulation of HOXA cluster gene expression in these and our models is likely an indirect effect mediated by the disruption of a HOXA/MEIS1 dependent auto-regulatory loop [50]. The strong overlap between genes downregulated upon inactivation of Kmt2a and inactivation of Men1 supports that the effect of Menin/Kmt2a inhibition in MN1-driven leukemias is a result of disrupting the Kmt2a complex. Overall, our data confirms that inhibition of the Menin/KMT2A interaction is a therapeutic strategy in the absence of KMT2Afusion proteins in selected AML subtypes.
The observation that KMT2A-rearranged leukemias are critically dependent on Menin [27] and more particularly the interaction between Menin and KMT2A [28] has prompted the development of small molecule inhibitors of this protein-protein interaction [51]. Several generations of improved inhibitors have demonstrated specific inhibition of leukemia cell growth in vitro, induction of differentiation as well as downregulation of both HOXA9 and MEIS1 expression [51][52][53]. Furthermore, small molecule inhibitors of the Menin/KMT2A interaction have been shown to induce complete remission as single agents in PDX models [35,54]. In steady state hematopoiesis, Menin was found to be dispensable, as acute loss of Men1 only causes minor cytopenias [55] and does not affect the frequency of hematopoietic stem cells (HSC) and other progenitors. Still, Men1 −/− HSCs were at a disadvantage compared to Men1 wt HSCs in repopulating secondary recipients after bone marrow ablation. Thus, this raises the concern that targeting the Menin/KMT2A interaction in leukemias that depend on wild type KMT2A could also negatively impact normal hematopoiesis. Prolonged treatment of non-leukemic mice with inhibitors of the Menin/Kmt2a interaction did not reveal any significant effect on normal hematopoiesis [35,54]. Similarly, we found that in a xenograft model of MN1-driven leukemia, VTP50469 was well tolerated at doses that decreased leukemic burden. Furthermore, no toxicity of a therapeutically effective dose was observed in a murine model and in PDX of NPM1c AML [45,54]. This suggests a therapeutic window for inhibition of the Menin/ KMT2A interaction in leukemias that rely on KMT2A. Error bars represent mean ± SEM of biological replicates (n = 5 animals per condition, unpaired double-sided t-test.). E Survival of mice NSG mice transplanted with UCSD-AML1 cells and treated with VTP50469 or control chow. VTP50469 chow was started at D14 posttransplant and continued throughout the experiment. Kaplan-Meier estimate, p < 0.0001 n = 10 animals per condition. F Leukemia burden in the bone marrow (left) and the spleen (right) at necropsy in VTP50469 versus control treated mice assessed by the percentage of human CD45 + , murine CD45 − cells. Error bars represent mean ± SEM, n = 10 animals per condition, unpaired double-sided t-test.
While the exact contribution of MN1 to leukemogenesis remains unclear, high levels of expression of MN1 consistently correlate with poor prognosis; whether it is found in the absence of any karyotypic anomalies [6][7][8] or when associated with rearrangement of the MN1 locus [4,56]. In addition, high levels of MN1 have been found in a subgroup of AML patients with dismal prognosis, those with complex karyotype or monosomy 5 and 7 [9]. Overall, for patients with high MN1 expression, current AML therapy remains inefficient. The data described here demonstrate that Menin specifically regulates a rare but key population of MN1driven leukemic cells, the LIC. LIC have shown decreased drug sensitivity compared to the bulk of the leukemia population [57] and have been directly linked to relapse [58]. Thus, inhibition of Menin might allow to specifically target the subpopulation of leukemia cells resistant to conventional chemotherapies. Life Sciences and Health) within the framework of the cancer plan [research training grants to CL], gifts from "Association Raphael" and "Association 111 des arts, Lyon" [to CL] as well as start-up funds from University of Colorado Denver, Hematology/Oncology Section, and the Children's Hospital Colorado Research Institute Hyundai Hope on Wheels [to KMB].
Author contributions CL and KMB designed the study. CL, JNH, MCK, SSR, FA, and AL performed experiments. PE provided Men1 f/f and Kmt2a SET −/− mice as well as critical expertise. GMM provided VTP50469 compound and chow, as well as critical expertise. HMX conducted data analysis and statistical analysis. CL and KMB wrote the manuscript.

Compliance with ethical standards
Conflict of interest GMM is an employee and shareholder of Syndax Pharmaceuticals Inc. PE owns Amgen stock and has consulted for Servier Oncology. CL received a research training grant from Institut Servier. All other authors declare no conflict of interest.
Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons. org/licenses/by/4.0/.